Home
Storia in 2 fonti
Lilly, Gilead lead pharma’s M&A boom
Deal volume in 2026 is substantially outpacing last year, and activity is being driven by interest in cancer and autoimmune disease drugs.
- ·
biopharmadive.com
Biotech M&A is accelerating. Track the deals that are happening here.
Catalyst is already the fourth biotech acquisition this month, continuing an acceleration of bigger-ticket deals that’s put 2026 on a faster pace than every year since at least…
- ·
pharmavoice.com
Lilly, Gilead lead pharma’s M&A boom
Deal volume in 2026 is substantially outpacing last year, and activity is being driven by interest in cancer and autoimmune disease drugs.